Follow

Ortoma AB

Nasdaq First North GM Stockholm (Sweden)

Ortoma develops surgical systems for implant surgery. The technology is based on 3D and is used to plan and position implants such as hip, knee, and back surgery. The vision is to facilitate the work for orthopaedic surgeons and increase the efficiency in each surgery case. A major part of the business is research and development.
Go to market

Sector:
HEALTH CARE
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
ORT B
SE0005676103
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Ortoma AB with ticker ORT B
Status
Active
Currency
SEK
First trading date
31 Mar 2014
Exercise
Sign in to buy
Rights issue
Sign in to buy
Rights issue
Sign in to buy
Rights issue
Sign in to buy
Directed issue
Sign in to buy
Rights issue
Sign in to buy
Market move
Sign in to buy
Remuneration issue
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
ORT TO2 B
SE0019353715
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in Ortoma AB with ticker ORT TO2 B
Status
Active
Currency
SEK
Trading period
09 Mar 2023 - 23 Nov 2023
Terms
One (1) warrant TO2 B entitles the holder to subscribe for one (1) new share for the price which corresponds to seventy (70) percent of the volume-weighted average trading price during the period of ten (10) trading days ending November 14, 2023, however, not less than SEK 4.0 and not more than SEK 10.0 per share. Subscription period with the support of warrants will take place between November 15, 2023 - November 28, 2023.
Exercise
Sign in to buy
Type
Ticker
ISIN
Market
SHARE
ORT B
SE0005676103
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Ortoma AB with ticker ORT B
Status
Active
Currency
SEK
First trading date
31 Mar 2014
Rights issue
Sign in to buy
Rights issue
Sign in to buy
Rights issue
Sign in to buy
Directed issue
Sign in to buy
Rights issue
Sign in to buy
Market move
Sign in to buy
Remuneration issue
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
ORT TO1 B
SE0005676111
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in Ortoma AB with ticker ORT TO1 B
Status
Archived
Currency
SEK
Trading period
31 Mar 2014 - 17 Feb 2015
Terms
One (1) warrant entitles the holder to subscribe for one (1) new B share for the price which corresponds to seventy (70) percent of the average volume-weighted price for the B share during the period of twenty (20) trading days ends two (2) banking days before the exercise period begins.
Update (30.01.2015). Information about warrants TO1 B.
Update (16.02.2015): Last trading day for warrants TO1 B.
Exercise
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
ORT TO2 B
SE0019353715
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in Ortoma AB with ticker ORT TO2 B
Status
Active
Currency
SEK
Trading period
09 Mar 2023 - 23 Nov 2023
Terms
One (1) warrant TO2 B entitles the holder to subscribe for one (1) new share for the price which corresponds to seventy (70) percent of the volume-weighted average trading price during the period of ten (10) trading days ending November 14, 2023, however, not less than SEK 4.0 and not more than SEK 10.0 per share. Subscription period with the support of warrants will take place between November 15, 2023 - November 28, 2023.
Exercise
Sign in to buy
People
Linus Byström
CEO
Gunnar Németh
Chairman of the board
Tommy Hansson
Board member
Roy Forslund
Board member
Matts Andersson
Board member
Jonny Nordqvist
Board member
Peter Möller
Board member
Yvonne Mårtensson
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Falkenbergsgatan 3
Zip code
412 85
City/district
Göteborg
Country
Sweden (SE)
Registration number
556611-7585
LEI code
549300YX458MQ26P4W97
First trade date
31 Mar 2014
Registration date
08 Jun 2001
Short name
ORT

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More